2024
Efficacy of long‐term risankizumab treatment for moderate‐to‐severe plaque psoriasis: Subgroup analyses by baseline characteristics and psoriatic disease manifestations through 256 weeks (LIMMitless trial)
Strober B, Bachelez H, Crowley J, Elewski B, Gooderham M, Menter A, Strohal R, Chen M, Wu T, Zhan T, Photowala H, Armstrong A. Efficacy of long‐term risankizumab treatment for moderate‐to‐severe plaque psoriasis: Subgroup analyses by baseline characteristics and psoriatic disease manifestations through 256 weeks (LIMMitless trial). Journal Of The European Academy Of Dermatology And Venereology 2024, 38: 864-872. PMID: 38179809, DOI: 10.1111/jdv.19748.Peer-Reviewed Original ResearchSevere plaque psoriasisLong-term efficacyPlaque psoriasisDisease manifestationsWeek 256Palmoplantar psoriasisSubgroup analysisDurable long-term efficacyOpen-label extension studyBaseline patient characteristicsProportion of patientsBody mass indexInflammatory skin diseaseMultiple clinical manifestationsPASI 90/100Psoriatic manifestationsRisankizumab treatmentBaseline characteristicsPatient characteristicsPsoriasis AreaSkin psoriasisMass indexClinical manifestationsArthritis statusPatient subgroups
2021
Tofacitinib for the Treatment of Refractory Palmoplantar Psoriasis: A Case Series
Muzumdar S, Leonardi C, Strober B. Tofacitinib for the Treatment of Refractory Palmoplantar Psoriasis: A Case Series. Journal Of Psoriasis And Psoriatic Arthritis 2021, 6: 93-98. DOI: 10.1177/2475530321995516.Peer-Reviewed Original ResearchPalmoplantar psoriasisCase seriesEfficacy of tofacitinibRecalcitrant palmoplantar psoriasisSubtypes of psoriasisPsoriasis refractorySystemic therapyPatients' qualityNew medicationsEffective therapyPsoriasis phenotypesSpecific cytokinesPsoriasisTofacitinibTherapyTreatmentMedicationsPatientsCytokinesSubtypes
2015
The Use of Methotrexate, Alone or in Combination With Other Therapies, for the Treatment of Palmoplantar Psoriasis.
Wald J, Klufas D, Strober B. The Use of Methotrexate, Alone or in Combination With Other Therapies, for the Treatment of Palmoplantar Psoriasis. Journal Of Drugs In Dermatology 2015, 14: 888-92. PMID: 26267735.Peer-Reviewed Original ResearchMeSH KeywordsAdalimumabAdolescentAdultAgedAged, 80 and overAnti-Inflammatory Agents, Non-SteroidalCyclosporineDermatologic AgentsDrug Therapy, CombinationEtanerceptFemaleFoot DermatosesHand DermatosesHumansImmunosuppressive AgentsInfliximabMaleMethotrexateMiddle AgedMycophenolic AcidPsoriasisSeverity of Illness IndexThalidomideUstekinumabYoung Adult
2012
A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 2
Strober BE, Clay Cather J, Cohen D, Crowley JJ, Gordon KB, Gottlieb AB, Kavanaugh AF, Korman NJ, Krueger GG, Leonardi CL, Schwartzman S, Sobell JM, Solomon GE, Young M. A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 2. Dermatology And Therapy 2012, 2: 2. PMID: 23205325, PMCID: PMC3510406, DOI: 10.1007/s13555-012-0002-x.Peer-Reviewed Original ResearchSevere psoriasisDifficult treatment scenariosPreferred therapeutic choiceLow-dose methotrexateOptimal treatment optionsCases of psoriasisDelphi consensus approachField of psoriasisErythrodermic psoriasisPalmoplantar psoriasisPustular psoriasisTopical therapySuch patientsTreatment optionsPsoriasis casesTherapeutic choiceClinical trialsConsensus panelPsoriasisScant dataDelphi exerciseLive meetingsPatientsTherapyExercise